UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 105

Sortiert nach

Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use

Multiple sclerosis international, 2019-01, Vol.2019, p.7151685-19

2019

Volltextzugriff (PDF)

Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

Lancet neurology, 2011-04, Vol.10 (4), p.338-348

2011

Volltextzugriff (PDF)

Health-related quality of life in multiple sclerosis: effects of natalizumab

Annals of neurology, 2007-10, Vol.62 (4), p.335-346

2007

Volltextzugriff (PDF)

A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing–remitting or secondary progressive multiple sclerosis

Multiple sclerosis, 2011-02, Vol.17 (2), p.181-191

2011

Volltextzugriff (PDF)

Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis

Annals of neurology, 2006-05, Vol.59 (5), p.780-787

2006

Volltextzugriff (PDF)

Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis

Multiple sclerosis and related disorders, 2014-09, Vol.3 (5), p.607-619

2014

Volltextzugriff (PDF)

Physical Activity Correlates With Neurological Impairment and Disability in Multiple Sclerosis

The journal of nervous and mental disease, 2008-06, Vol.196 (6), p.492-495

2008

Volltextzugriff (PDF)

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis

Annals of neurology, 2010-10, Vol.68 (4), p.494-502

2010

Volltextzugriff (PDF)

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

Journal of neurology, 2009-06, Vol.256 (6), p.1035-1037

2009

Volltextzugriff (PDF)

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

Journal of neurology, 2009-03, Vol.256 (3), p.405-415

2009

Volltextzugriff (PDF)

A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-I2 and -23 monoclonal antibody in patients with relapsing―remitting or secondary progressive multiple sclerosis

Multiple sclerosis, 2011, Vol.17 (2), p.181-191

2011

Volltextzugriff (PDF)

A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota

Neurology, 1990-05, Vol.40 (5), p.780

1990

Volltextzugriff (PDF)

Natalizumab plus interferon beta-la for relapsing multiple sclerosis

The New England journal of medicine, 2006, Vol.354 (9), p.911-923

2006

Volltextzugriff (PDF)

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

Lancet neurology, 2011-04, Vol.10 (4), p.338-348

2011

Volltextzugriff (PDF)

Update on the Epidemiology of Multiple Sclerosis

Mayo Clinic proceedings, 1989-07, Vol.64 (7), p.808-817

1989

Volltextzugriff (PDF)

Terminal component of complement (C9) in the cerebrospinal fluid of patients with multiple sclerosis and neurologic controls

Neurology, 1990-05, Vol.40 (5), p.855

1990

Volltextzugriff (PDF)

Hand Lesions as a Sign of Bulimia: The authors reply

Mayo Clinic proceedings, 1985-01, Vol.60 (1), p.50-50

1985

Volltextzugriff (PDF)

A Physical Sign of Bulimia

Mayo Clinic proceedings, 1984-10, Vol.59 (10), p.722-722

1984

Volltextzugriff (PDF)

Revisiting an old riddle: what determines genetic diversity levels within species?

PLoS biology, 2012-09, Vol.10 (9), p.e1001388-e1001388

2012

Volltextzugriff (PDF)

The polymeric mucin Muc5ac is required for allergic airway hyperreactivity

Nature communications, 2015-02, Vol.6 (1), p.6281-6281, Article 6281

2015

Volltextzugriff (PDF)

DNA barcoding of the National Museum of Natural History reptile tissue holdings raises concerns about the use of natural history collections and the responsibilities of scientists in the molecular age

PloS one, 2022-03, Vol.17 (3), p.e0264930-e0264930

2022

Volltextzugriff (PDF)

A Carbon/Oxygen-dominated Atmosphere Days after Explosion for the “Super-Chandrasekhar” Type Ia SN 2020esm

The Astrophysical journal, 2022-03, Vol.927 (1), p.78

2022

Volltextzugriff (PDF)

Validity of Wearable Activity Monitors during Cycling and Resistance Exercise

Medicine and science in sports and exercise, 2018-03, Vol.50 (3), p.624-633

2018

Volltextzugriff (PDF)

Parsing components of auditory predictive coding in schizophrenia using a roving standard mismatch negativity paradigm

Psychological medicine, 2019-05, Vol.49 (7), p.1195-1206

2019

Volltextzugriff (PDF)

1 – 25 von 105

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(92)
Mit Volltextzugriff
(96)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(81)
Life Sciences & Biomedicine
(54)
Humans
(49)
Female
(41)
Male
(35)
Animals
(25)
Biological And Medical Sciences
(22)
Adult
(20)
Middle Aged
(20)
Multidisciplinary Sciences
(19)
Science & Technology - Other Topics
(19)
Clinical Neurology
(17)
Medical Sciences
(17)
Neurology
(17)
Neurosciences & Neurology
(17)
Genomes
(11)
Treatment Outcome
(11)
Genomics
(10)
Mammals
(9)
Mice
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use

Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

Health-related quality of life in multiple sclerosis: effects of natalizumab

A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing–remitting or secondary progressive multiple sclerosis

Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis

Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis

Physical Activity Correlates With Neurological Impairment and Disability in Multiple Sclerosis

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-I2 and -23 monoclonal antibody in patients with relapsing―remitting or secondary progressive multiple sclerosis

A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota

Natalizumab plus interferon beta-la for relapsing multiple sclerosis

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

Update on the Epidemiology of Multiple Sclerosis

Terminal component of complement (C9) in the cerebrospinal fluid of patients with multiple sclerosis and neurologic controls

Hand Lesions as a Sign of Bulimia: The authors reply

A Physical Sign of Bulimia

Revisiting an old riddle: what determines genetic diversity levels within species?

The polymeric mucin Muc5ac is required for allergic airway hyperreactivity

DNA barcoding of the National Museum of Natural History reptile tissue holdings raises concerns about the use of natural history collections and the responsibilities of scientists in the molecular age

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)

A Carbon/Oxygen-dominated Atmosphere Days after Explosion for the “Super-Chandrasekhar” Type Ia SN 2020esm

Validity of Wearable Activity Monitors during Cycling and Resistance Exercise

Parsing components of auditory predictive coding in schizophrenia using a roving standard mismatch negativity paradigm

Suchergebnisse filtern